PR90470

South-Korean biotech Y-Biologics and French mid-pharma Pierre Fabre enter into a worldwide exclusive license agreement in the highly innovative field of immuno-oncology

DAEJEON, South Korea and CASTRES, France, July 6, 2021 29 /PRNewswire=KYODO JBN/ --

The South Korean biotech company Y-Biologics and the French pharmaceutical

group Pierre Fabre have entered into a license agreement granting worldwide

exclusive rights to Pierre Fabre to develop and commercialize a family of human

antibodies generated through the phage display human antibody Ymax (R) - ABL

library owned by Y-Biologics.

These antibodies have been functionally validated by the Pierre Fabre R&D teams

for their specific properties on a pivotal immuno-oncology target acting on the

tumoral microenvironment. Pierre Fabre intends to select  a new therapeutic

candidate in immuno-oncology for further developments.

This licensing agreement results from the strong and now proven complementarity

between the two companies who have been collaborating since 2018. The final

objective pursued by Y-Biologics and Pierre Fabre is to provide patients with

innovative drugs to target refractory or relapsing cancer, taking advantage of

the immune infiltrate to inhibit the growth of tumor cells.

This new milestone reached by the two companies reveals the effectiveness of

the scientific means put in place by Y-Biologics, associated with the high

expertise of Pierre Fabre in oncology.

Young Woo Park, CEO of Y-Biologics, stated: “We are very pleased to sign our

first license agreement with Pierre Fabre. The collaboration between

Y-Biologics and Pierre Fabre which is being conducted based on mutual trust, is

expected to further advance the development of innovative immuno-oncology

therapeutics targeting the tumor microenvironment.”

"Since the beginning of our partnership, the collaboration with Y-Biologics has

been very efficient and fruitful. Their library has allowed us to identify a

family of human antibodies against a promising target defined by our

researchers at our dedicated Center of Immunology. This new exciting license

agreement will allow us to further support the development of this therapy for

the benefit of patients," added Nathalie Corvaïa, Head of Immuno-Oncology

Research, Center of Immunology Pierre Fabre (CIPF).  

Further information about Y-Biologics can be found at

http://ybiologics.com/eng/main/

Further information about Pierre Fabre can be found at www.pierre-fabre.com /

@PierreFabre.

Logo -

https://mma.prnewswire.com/media/1557487/Y_Biologics_Pierre_Fabre_Logo.jpg

Pierre Fabre:

Anne Kerveillant, Communication Manager

anne.kerveillant@pierre-fabre.com

Y-Biologics:

Dong-Ock Chang

dochang@ybiologics.com

Joint source: Pierre Fabre and Y-Biologics